The nonclassical form of congenital adrenal cortical dysfunction in adolescent girls

The study was undertaken to define the frequency of nonclasslcal 21-hydroxylase deficiency confirmed by CYP21 gene mutations in girls with pubertal hyperandrogenlsm, to estimate the value of clinical and hormonal markers of nonclasslcal 21-hydroxylase deficiency. Eighty-five girls aged 5-17 years who had hyperandrogenlsm (pubertas precox, hirsutism, acne vulgaris). All the examinees underwent adrenocorticotropic hormone (ACTH) (Synacthen-depot) test. After detecting the hormonal markers oj"nonclassical21-hy-droxylase deficiency (the baseline level of 17- О HP being was above 9 nmol/l and/or above 45 nmol/l after A CTH stimulation), the authors analyzed the most common CYP21 gene mutations. The frequency of nonclassical 21-hydroxylase deficiency supported by CYP21 mutations In the girls with hyperadrogenlsm was 8.3%. There were no clinical differences between the nonclassical form of 21-hydroxylase deficiency and other forms of hyperandrogenlsm. The high baseline 17-OHP ( > 20 nmol/l) is the most specific hormonal marker of nonclasslcal 21-hydroxylase deficiency. Glucocorticoid therapy is indicated for patients with substantially accelerated growth and bone maturation and in those with menstrual irregularities as oligomenorrhea or amenorrhea.

21-Hydroxylase deficiency, nonclassical form of congenital adrenal cortical dysfunction, hyperadrogenlsm, pubertas precox

1. Дедов И. И., Семичева Т. В., Петеркова В. А. Половое развитие детей: норма и патология. -М., 2002.

2. Дедов И. И., Калинченко Н. Ю., Семичева Т. В. и др.//Пробл. эндокринол. -2004. -N9 4. -С. 3-б.

3. Карева М. А., Дедов И. И., Орловский И. В. и др.//Молекул, мед. -2004. -№ 2. -С. 60-65.

4. Azziz Я, Dewailly D., Owerbach D.//J. Clin. Endocrinol. Me-tab. -1994. -Vol. 78, N 4. -P. 810-815.

5. Dacou-Voutetakis C, Dracopoulou M.//J. Clin. Endocrinol. Metab. -1999. -Vol. 84, N 5. -P. 1570-1574.

6. Deneux C, Tardy V., Dib A. et al.//J. Clin. Endocrinol. Metab. -2001. -Vol. 86, N 1. -P. 207-213.

7. Feldman S., Billaud L., Tharlabard J. et al.//J. Clin. Endocrinol. Metab. -1992. -Vol. 74, N 3. -P. 635-639.

8. Gemmel N. J., Aklyama S.//Trends Genet. -1996. -Vol. 12, N 9. -P. 338-339.

9. Hawkins L., Chasahw F., Blethen S.//J. Clin. Endocrinol. Metab. -1992. -Vol. 74, N 2. -P. 248-253.

10. Moran C, Azziz R.//Semin. Reprod. Med. -2003. -Vol. 21, N 3. -P. 295-300.

11. Morel Y, Miller W.//Adv. Hum. Genet. -1991. -Vol. 20. -P. 1-68.

12. Morris A., Relter O., Geffner M. et al.//J. Clin. Endocrinol. Metab. -1989. -Vol. 69, N 4. -P. 709-715.

13. New M., Lorenzen F., Lerner A. et al.//J. Clin. Endocrinol. Metab. -1983. -Vol. 57, N 2. -P. 320-326.

14. Sherman S., Aston S., Morton N. et al.//Am. J. Hum. Genet. -1988. -Vol. 42, N 2. -P. 830-838.

15. Speiser P., Dupont В., Rubinstein P. et al.//Am. J. Hum. Genet. -1985. -Vol. 37, N 4. -P. 650-657.

16. Tajima Т., Fujieda K., Nakae J. et al.//Endocr. J. -1998. -Vol. 45, N 4. -P. 493-497.

17. Wedell A., Luthman H.//Hum. Mol. Genet. -1993. -Vol. 2, N 5. -P. 499-504.

18. Weintrob N., Brautbar C, Pertielan A. et al.//Eur. J. Endocrinol. -2000. -Vol. 143, N 1. -P. 397-403.

19. White P., Speiser P.//Endocr. Rev. -2000. -Vol. 21, N 3. P. 245-291.

20. Yarman S., Dursun A., Oguz F., Alagbl F.//Endocr. J. -2004. -Vol. 51, N 1. -P. 31-36.